Regencell Bioscience Holdings Ltd Financials

RGC

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE June

Financial Health Signals

Piotroski F-Score Weak

1/9

Regencell Bioscience Holdings Ltd passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.87x

For every $1 of reported earnings, Regencell Bioscience Holdings Ltd generates $0.87 in operating cash flow (-$3.1M OCF vs -$3.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Regencell Bioscience Holdings Ltd (RGC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$3.4M

YoY+15.4%

Regencell Bioscience Holdings Ltd's EBITDA was -$3.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.4% from the prior year.

Free Cash Flow

-$3.3M

YoY+18.5%

Regencell Bioscience Holdings Ltd generated -$3.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 18.5% from the prior year.

Net Income

-$3.6M

YoY+16.7%

Regencell Bioscience Holdings Ltd reported -$3.6M in net income in fiscal year 2025. This represents an increase of 16.7% from the prior year.

EPS (Diluted)

$-0.72

Regencell Bioscience Holdings Ltd earned $-0.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 17.2% from the prior year.

Cash & Debt

$2.4M

YoY-18.3%

5Y CAGR+44.3%

Regencell Bioscience Holdings Ltd held $2.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

494M

Regencell Bioscience Holdings Ltd had 494M shares outstanding in fiscal year 2025. This represents an increase of 3700.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$948K

YoY-11.1%

5Y CAGR+19.7%

Regencell Bioscience Holdings Ltd invested $948K in research and development in fiscal year 2025. This represents a decrease of 11.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$153K

YoY+2740.2%

5Y CAGR+5.3%

Regencell Bioscience Holdings Ltd invested $153K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 2740.2% from the prior year.

RGC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$948K-11.1%	$1.1M-32.6%	$1.6M-37.0%	$2.5M+473.1%	$438K+13.5%	$386K
SG&A Expenses	$2.8M-20.6%	$3.5M-20.0%	$4.4M-12.8%	$5.1M+439.6%	$941K+201.8%	$312K
Operating Income	-$3.8M+20.4%	-$4.7M+24.5%	-$6.3M+17.6%	-$7.6M-451.5%	-$1.4M-70.0%	-$812K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.6M+16.7%	-$4.3M+26.7%	-$5.9M+21.1%	-$7.4M-452.9%	-$1.3M-65.8%	-$812K
EPS (Diluted)	$-0.72	$-0.87+26.9%	$-1.19-105.2%	$-0.58-346.2%	$-0.13-62.5%	$-0.08

Metric	Q2'25	Q2'24	Q2'23	Q2'22	Q2'21	Q2'20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

RGC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.8M-31.8%	$8.4M-33.1%	$12.6M-30.0%	$18.0M+5197.6%	$340K-33.8%	$514K
Current Assets	$4.9M-39.6%	$8.1M-30.2%	$11.6M-29.3%	$16.4M+24499.6%	$67K-82.7%	$387K
Cash & Equivalents	$2.4M-18.3%	$3.0M+89.2%	$1.6M-75.6%	$6.4M+10700.7%	$59K-84.6%	$387K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$895K+307.9%	$220K-65.3%	$632K-32.6%	$938K-78.4%	$4.3M+37.1%	$3.2M
Current Liabilities	$664K+242.8%	$194K-68.1%	$607K+5.0%	$578K-86.7%	$4.3M+37.1%	$3.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.9M-40.9%	$8.2M-31.7%	$12.0M-29.5%	$17.1M+526.9%	-$4.0M-50.8%	-$2.7M
Retained Earnings	-$25.2M-16.6%	-$21.6M-24.8%	-$17.3M-51.3%	-$11.4M-186.2%	-$4.0M-50.8%	-$2.7M

Metric	Q2'25	Q2'24	Q2'23	Q2'22	Q2'21	Q2'20
Total Assets	$5.8M-31.8%	$8.4M-33.1%	$12.6M-30.0%	$18.0M+5197.6%	$340K-33.8%	$514K
Current Assets	$4.9M-39.6%	$8.1M-30.2%	$11.6M-29.3%	$16.4M+24499.6%	$67K-82.7%	$387K
Cash & Equivalents	$2.4M-18.3%	$3.0M+89.2%	$1.6M-75.6%	$6.4M+10700.7%	$59K-84.6%	$387K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$895K+307.9%	$220K-65.3%	$632K-32.6%	$938K-78.4%	$4.3M+37.1%	$3.2M
Current Liabilities	$664K+242.8%	$194K-68.1%	$607K+5.0%	$578K-86.7%	$4.3M+37.1%	$3.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.9M-40.9%	$8.2M-31.7%	$12.0M-29.5%	$17.1M+526.9%	-$4.0M-50.8%	-$2.7M
Retained Earnings	-$25.2M-16.6%	-$21.6M-24.8%	-$17.3M-51.3%	-$11.4M-186.2%	-$4.0M-50.8%	-$2.7M

RGC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$3.1M+22.2%	-$4.0M+19.4%	-$5.0M+5.8%	-$5.3M-586.4%	-$767K-5.6%	-$727K
Capital Expenditures	$153K+2740.2%	$5K-80.4%	$27K-96.5%	$781K	N/A	$118K
Free Cash Flow	-$3.3M+18.5%	-$4.0M+19.7%	-$5.0M+17.5%	-$6.0M	N/A	-$844K
Investing Cash Flow	$2.7M-48.8%	$5.2M+8789.1%	$59K+100.5%	-$10.8M	N/A	-$118K
Financing Cash Flow	N/A	$102K-24.2%	$135K-99.4%	$22.4M+4995.1%	$440K-55.5%	$988K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q2'24	Q2'23	Q2'22	Q2'21	Q2'20
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

RGC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-62.3%-11.3pp	-51.0%-4.5pp	-46.5%-5.2pp	-41.3%+354.6pp	-395.9%-237.9pp	-158.0%
Current Ratio	7.39-34.5	41.92+22.8	19.15-9.3	28.46+28.4	0.02-0.1	0.12
Debt-to-Equity	0.18+0.2	0.03-0.0	0.050.0	0.06+1.1	-1.09+0.1	-1.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q2'24	Q2'23	Q2'22	Q2'21	Q2'20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	7.39-34.5	41.92+22.8	19.15-9.3	28.46+28.4	0.02-0.1	0.12
Debt-to-Equity	0.18+0.2	0.03-0.0	0.050.0	0.06+1.1	-1.09+0.1	-1.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Elanco Animal Health ELAN

$12.3B

Alkermes Plc ALKS

$5.5B

Lantheus Holding LNTH

$4.6B

Prestige Consmr Healthcare Inc PBH

$3.2B

Amneal Pharmaceuticals Inc AMRX

$4.6B

Frequently Asked Questions

Is Regencell Bioscience Holdings Ltd profitable?

No, Regencell Bioscience Holdings Ltd (RGC) reported a net income of -$3.6M in fiscal year 2025.

What is Regencell Bioscience Holdings Ltd's earnings per share (EPS)?

Regencell Bioscience Holdings Ltd (RGC) reported diluted earnings per share of $-0.72 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Regencell Bioscience Holdings Ltd's EBITDA?

Regencell Bioscience Holdings Ltd (RGC) had EBITDA of -$3.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Regencell Bioscience Holdings Ltd's free cash flow?

Regencell Bioscience Holdings Ltd (RGC) generated -$3.3M in free cash flow during fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Regencell Bioscience Holdings Ltd's operating cash flow?

Regencell Bioscience Holdings Ltd (RGC) generated -$3.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Regencell Bioscience Holdings Ltd's total assets?

Regencell Bioscience Holdings Ltd (RGC) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Regencell Bioscience Holdings Ltd's capital expenditures?

Regencell Bioscience Holdings Ltd (RGC) invested $153K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Regencell Bioscience Holdings Ltd spend on research and development?

Regencell Bioscience Holdings Ltd (RGC) invested $948K in research and development during fiscal year 2025.

How many shares does Regencell Bioscience Holdings Ltd have outstanding?

Regencell Bioscience Holdings Ltd (RGC) had 494M shares outstanding as of fiscal year 2025.

What is Regencell Bioscience Holdings Ltd's current ratio?

Regencell Bioscience Holdings Ltd (RGC) had a current ratio of 7.39 as of fiscal year 2025, which is generally considered healthy.

What is Regencell Bioscience Holdings Ltd's debt-to-equity ratio?

Regencell Bioscience Holdings Ltd (RGC) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Regencell Bioscience Holdings Ltd's return on assets (ROA)?

Regencell Bioscience Holdings Ltd (RGC) had a return on assets of -62.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Regencell Bioscience Holdings Ltd's cash runway?

Based on fiscal year 2025 data, Regencell Bioscience Holdings Ltd (RGC) had $2.4M in cash against an annual operating cash burn of $3.1M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Regencell Bioscience Holdings Ltd's Piotroski F-Score?

Regencell Bioscience Holdings Ltd (RGC) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Regencell Bioscience Holdings Ltd's earnings high quality?

Regencell Bioscience Holdings Ltd (RGC) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.